Evofem Biosciences (OTCID: EVFM) reported third-quarter 2026 net sales of $4.6 million, compared with $5.0 million in the prior-year period. GAAP net income was $1.0 million, while net income attributable to common stockholders was $0.9 million.
The company reported $0.7 million of income from operations and $3.9 million in total operating expenses for the quarter ended September 30, 2026.
- Basic earnings per share were $0.01; diluted earnings per share were $(0.00).
- Restricted cash and cash equivalents totaled $0.3 million at September 30, 2026, compared with $0.6 million at December 31, 2025.
- Evofem contracted with a second pharmaceutical manufacturer to produce PHEXX.
- The company shipped its 500,000th box of PHEXX in July 2026.
